Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report

Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report

Abstract Objective Cardiovascular (CV) outcome trials have shown that in patients with type 2 diabetes (T2D), treatment with sodium-glucose cotransporter-2 inhibitors (SGLT-2i) reduces CV mortality and hospital admission rates for heart failure (HF). However, the mechanisms behind these benefits are...

Full description

Bibliographic Details
Main Authors: Lucia Leccisotti, Francesca Cinti, Gian Pio Sorice, Domenico D’Amario, Margherita Lorusso, Maria Angela Guzzardi, Teresa Mezza, Shawn Gugliandolo, Camilla Cocchi, Umberto Capece, Luca Indovina, Pietro Manuel Ferraro, Patricia Iozzo, Filippo Crea, Alessandro Giordano, Andrea Giaccari
Format: Article
Language:English
Published: BMC 2022-09-01
Series:Cardiovascular Diabetology
Subjects:
Diabetes
Metabolism
Myocardial blood flow
Perfusion
PET
SGLT-2
Online Access:https://doi.org/10.1186/s12933-022-01607-4

Internet

https://doi.org/10.1186/s12933-022-01607-4

Similar Items